AGENDA
Session Learning Objectives
Upon completion of this activity, participants will:
Have increased knowledge regarding the
- - Criteria used to determine if a patient should be assessed for high risk of breast cancer
- Models used to assess breast cancer risk - - Relationship between breast density and breast cancer risk
- Predictive value of BI-RADS® - - Role of contrast-enhanced mammography in breast cancer screening
Have greater confidence in their ability to
-
- Incorporate interprofessional strategies into breast cancer care
Session Learning Objectives
Upon completion of this activity, participants will:
-
Have increased knowledge regarding the
- Comparability of PET images for assessment of treatment response
- Clinical data evaluating ER-targeting and PET tracers in ILC
- Diagnostic potential of artificial intelligence
- Utilization of radiomics and radiogenomics to characterize tumors for more precise imaging and treatment -
Have greater confidence in their ability to
- Incorporate interprofessional strategies into breast cancer care
Session Learning Objectives
After completion of this activity, participants will
-
Have increased knowledge regarding the
-
-
- Differences among genomic assays available to patients with HR-positive early breast cancer
- Clinical data supporting the use of adjuvant therapies in early HR-positive early breast cancer - Have greater competence related to
-
- Mitigation of adverse events that present for patients receiving therapy for HR-positive early breast cancer
-
-
Have greater confidence in their ability to incorporate interprofessional strategies into breast cancer care
Session Learning Objectives
Upon completion of this activity, participants will:
-
Have increased knowledge regarding the
-
-
- Mechanism of action of oral SERDs
-
- Clinical trial data associated with other endocrine therapies of consideration for the care of patients with advanced/metastatic HR-positive breast cancer
-
- Clinical trial data about CKD4/6 inhibitors in the advanced/metastatic HR-positive breast cancer
-
-
Have greater confidence in their ability to incorporate interprofessional strategies into breast cancer care
Session Learning Objectives
-
Have increased knowledge regarding the
-
-
- Therapeutic opportunities targeting mutations of consideration in patients with HR-positive breast cancer
-
- Mechanism of actions of antibody drug conjugates
-
-
Have greater competence related to
-
- Managing toxicities associated with therapies used in HR-positive breast cancer
-
-
Have greater confidence in their ability to incorporate interprofessional strategies into breast cancer care
Session Learning Objectives
Upon completion of this activity, participants will
-
Have increased knowledge regarding the
-
- Clinical data associated with treatment strategies for pre-operative treatment of HER2-positive breast cancer
- Definition of high-risk residual HER2-positive breast cancer -
- Escalation and de-escalation strategies in HER2-positive early breast cancer
-
-
Have greater confidence in their ability to incorporate interprofessional strategies into breast cancer care
Session Learning Objectives
Upon completion of this activity, participants will
-
Have increased knowledge regarding the
- Clinical data associated with emerging HER2-directed antibody drug conjugates for the treatment of HER2-positive breast cancer
- Clinical data associated with emerging novel therapies for the treatment of HER2-positive breast cancer -
-
Have greater competence related to
-
- Selecting the appropriate treatments for patients with metastatic HER2-positive breast cancer
-
- Managing toxicities associated with therapies used in HER2-positive breast cancer
Have greater confidence in their ability to incorporate interprofessional strategies into breast cancer care
Session Learning Objectives
Upon completion of this activity, participants will:
-
Have increased knowledge regarding the
- Emerging opportunities targeting HER2-low patients with breast cancer
- Interpretation of testing results to determine therapeutic approaches for patients
Have greater competence related to -
- Utilizing the overall prognosis of a patient with HER2-positive brain metastases to develop a treatment plan
Have greater confidence in their ability to incorporate interprofessional strategies into breast cancer care
Session Learning Objectives
Upon completion of this activity, participants will:
-
Have increased knowledge regarding the
- Clinical data associated with the impact of ctDNA in early-stage triple negative breast cancer -
-
Have greater competence related to
-
- Selecting the appropriate systemic therapy for patients with early-stage triple negative breast cancer
- Mitigation of adverse events that present for patients receiving therapy for early-stage triple negative breast cancer -
-
Have greater confidence in their ability to incorporate interprofessional strategies into breast cancer care
Session Learning Objectives
Upon completion of this activity, participants will:
-
Have increased knowledge regarding
- Clinical trials investigating emerging small molecules in metastatic triple negative breast cancer
- Emerging data related to novel therapies for the management of patients with metastatic triple negative breast cancer
- Concerns associated with brain metastases in triple negative breast cancer -
-
Have greater competence related to
-
- Incorporating guideline-based decision making into the development of treatment plans for patients with metastatic triple negative breast cancer
- Incorporating shared decision into the development of treatment plans for patients with breast cancer -
Have greater confidence in their ability to incorporate interprofessional strategies into breast cancer care